Russ Belden is a biotech commercialization leader with over 33 years of senior leadership experience in strategic marketing, sales management, sales training, and product development. Starting as employee 10 in Genentech’s SSF Commercial organization, he spent 16 years there launching products/indications across multiple therapeutic areas, including playing a pivotal role in launching their BioOncology franchise and left as the Director of Hematology Sales.
As Founder/President & CEO of Bridge Consulting LLC, he has worked with over 60 emerging biotech companies over the past 17 years. In addition to commercial assessments for preclinical to Phase 2 companies, Russ provides critical commercial leadership to Phase 3 emerging biotech companies as an interim Chief Commercial Officer (iCCO). As the company’s iCCO he leads all the commercialization imperatives, establishes the “blueprint” for the Commercial / Medical Affairs organization and develops a 3-year expense budget including all commercialization costs enabling the company to successfully position its lead product(s) for commercial launch while absorbing the risk of a potentially negative Phase 3 readout. Russ is currently the iCCO at three Phase 3 companies. He also serves as the Commercial Expert for the California Life Sciences Institute’s (CLSI) FAST program. Russ earned a BS in Pharmacy from the University of New York @ Buffalo and completed 2/3 of a Masters in Marketing program from the University of Texas @ Dallas.